Spruce Biosciences, Inc. Research and Development Expense
Spruce Biosciences, Inc. (SPRB) reported Research and Development Expense of $12.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- Spruce Biosciences, Inc. research and development expense for the quarter ending 2026-06-30 was $12.16M.
- Spruce Biosciences, Inc. research and development expense for the quarter ending 2026-03-31 was $7.58M, a 30.10% decline year-over-year.
- Spruce Biosciences, Inc. research and development expense for the quarter ending 2025-12-31 was $4.10M, a 80.87% decline year-over-year.
- Spruce Biosciences, Inc. research and development expense for the quarter ending 2025-09-30 was $5.01M, a 23.54% decline year-over-year.
- Spruce Biosciences, Inc. research and development expense for fiscal 2025 was $19.52M, a 57.94% decline from fiscal 2024.
- Spruce Biosciences, Inc. research and development expense for fiscal 2024 was $46.42M, a 6.10% decline from fiscal 2023.
- Spruce Biosciences, Inc. research and development expense for fiscal 2023 was $49.43M, a 40.44% increase from fiscal 2022.
- Spruce Biosciences, Inc. research and development expense for fiscal 2022 was $35.20M, a 14.66% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.16M 10-Q · filed 2026-08-12 | $19.74M 10-Q · filed 2026-08-12 | $23.84M derived: sum of 3 quarters · filed 2026-08-12 | $28.85M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $7.58M 10-Q · filed 2026-05-13 | $11.68M derived: sum of 2 quarters · filed 2026-05-13 | $16.69M derived: sum of 3 quarters · filed 2026-05-13 | $16.26M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $9.12M derived: sum of 2 quarters · filed 2026-03-09 | $8.69M derived: sum of 3 quarters · filed 2026-08-12 | $19.52M 10-K · filed 2026-03-09 |
| 2025-09-30 | $5.01M 10-Q · filed 2025-11-10 | $4.58M derived: sum of 2 quarters · filed 2026-08-12 | $15.42M 10-Q · filed 2025-11-10 | $36.88M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$430.00K 10-Q · filed 2026-08-12 | $10.41M 10-Q · filed 2026-08-12 | $31.86M derived: sum of 3 quarters · filed 2026-08-12 | $38.42M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $10.84M 10-Q · filed 2026-05-13 | $32.29M derived: sum of 2 quarters · filed 2026-05-13 | $38.85M derived: sum of 3 quarters · filed 2026-05-13 | $46.94M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $21.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $28.01M derived: sum of 2 quarters · filed 2026-03-09 | $36.10M derived: sum of 3 quarters · filed 2026-03-09 | $46.42M 10-K · filed 2026-03-09 |
| 2024-09-30 | $6.55M 10-Q · filed 2025-11-10 | $14.64M derived: sum of 2 quarters · filed 2025-11-10 | $24.96M 10-Q · filed 2025-11-10 | $36.06M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $8.09M 10-Q · filed 2025-08-14 | $18.41M 10-Q · filed 2025-08-14 | $29.51M derived: sum of 3 quarters · filed 2025-08-14 | $43.00M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $10.32M 10-Q · filed 2025-05-06 | $21.42M derived: sum of 2 quarters · filed 2025-05-06 | $34.91M derived: sum of 3 quarters · filed 2025-05-06 | $48.04M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $11.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $24.59M derived: sum of 2 quarters · filed 2025-04-15 | $37.72M derived: sum of 3 quarters · filed 2025-04-15 | $49.43M 10-K · filed 2025-04-15 |
| 2023-09-30 | $13.49M 10-Q · filed 2024-11-12 | $26.62M derived: sum of 2 quarters · filed 2024-11-12 | $38.33M 10-Q · filed 2024-11-12 | $47.17M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $13.13M 10-Q · filed 2024-08-12 | $24.84M 10-Q · filed 2024-08-12 | $33.68M derived: sum of 3 quarters · filed 2024-08-12 | $42.47M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $11.71M 10-Q · filed 2024-05-13 | $20.55M derived: sum of 2 quarters · filed 2024-05-13 | $29.34M derived: sum of 3 quarters · filed 2024-05-13 | $38.40M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $8.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $17.63M derived: sum of 2 quarters · filed 2024-03-18 | $26.69M derived: sum of 3 quarters · filed 2024-03-18 | $35.20M 10-K · filed 2024-03-18 |
| 2022-09-30 | $8.79M 10-Q · filed 2023-11-13 | $17.85M derived: sum of 2 quarters · filed 2023-11-13 | $26.36M 10-Q · filed 2023-11-13 | $32.62M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $9.06M 10-Q · filed 2023-08-14 | $17.57M 10-Q · filed 2023-08-14 | $23.83M derived: sum of 3 quarters · filed 2023-08-14 | $32.43M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $8.51M 10-Q · filed 2023-05-15 | $14.77M derived: sum of 2 quarters · filed 2023-05-15 | $23.37M derived: sum of 3 quarters · filed 2023-05-15 | $32.49M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $6.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $14.87M derived: sum of 2 quarters · filed 2023-03-16 | $23.98M derived: sum of 3 quarters · filed 2023-03-16 | $30.70M 10-K · filed 2023-03-16 |
| 2021-09-30 | $8.61M 10-Q · filed 2022-11-10 | $17.73M derived: sum of 2 quarters · filed 2022-11-10 | $24.44M 10-Q · filed 2022-11-10 | $30.25M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $9.12M 10-Q · filed 2022-08-10 | $15.83M 10-Q · filed 2022-08-10 | $21.65M derived: sum of 3 quarters · filed 2022-08-10 | $29.42M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $6.71M 10-Q · filed 2022-05-11 | $12.53M derived: sum of 2 quarters · filed 2022-05-11 | $20.30M derived: sum of 3 quarters · filed 2022-05-11 | $25.96M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $5.81M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $13.58M derived: sum of 2 quarters · filed 2022-03-14 | $19.25M derived: sum of 3 quarters · filed 2022-03-14 | $23.85M 10-K · filed 2022-03-14 |
| 2020-09-30 | $7.77M 10-Q · filed 2021-11-15 | $13.43M derived: sum of 2 quarters · filed 2021-11-15 | $18.04M 10-Q · filed 2021-11-15 | $20.89M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $5.66M 10-Q · filed 2021-08-10 | $10.27M 10-Q · filed 2021-08-10 | $13.12M derived: sum of 3 quarters · filed 2021-08-10 | $15.23M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $4.61M 10-Q · filed 2021-05-12 | $7.46M derived: sum of 2 quarters · filed 2021-05-12 | $9.56M derived: sum of 3 quarters · filed 2021-05-12 | |
| 2019-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | $4.96M derived: sum of 2 quarters · filed 2021-03-22 | $10.82M 10-K · filed 2021-03-22 | |
| 2019-09-30 | $2.11M 10-Q · filed 2020-11-18 | $7.97M 10-Q · filed 2020-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |